pharmaphorum
JANUARY 29, 2021
Sangamo CEO Sandy Macrae told us how his company is being cautious about the hype and finding ways to be financially viable in an emerging space. Maybe in 50 years’ time we’ll be using gene editing to lower cholesterol, but it won’t replace statins in anyone but those with life threatening mutations for a long time”.
The Pharma Data
OCTOBER 20, 2020
MD Anderson has historically collaborated with biotechs and pharma companies to conduct cancer therapy research. Targeted therapies, genetic sequencing, gene editing, immunotherapies. Ochsner Health and LSU Health Shreveport have offered themselves as additional trial sites to increase patient access to studies.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
FEBRUARY 13, 2023
Gene therapies are an attractive way of targeting the underlying genetic mutations, but traditional approaches cannot be used while targeting mutations for Dravet Syndrome, forcing researchers to develop new ways. Meanwhile, others are researching the link between gene variation and different responses to treatments.
XTalks
DECEMBER 20, 2023
In 2024, pharma companies and emerging biotechs will improve candidate safety profiles and reduce off-target effects by exploiting predictive intelligence unlocked by AI,” she predicts. CRISPR Gene Editing Therapeutics CRISPR/Cas-9 technology makes lists like this almost every year, and for good reason.
XTalks
DECEMBER 29, 2022
In 2022 alone, the US regulator approved four new gene therapies, showing the high interest in getting these therapies to market. In 2023, a number of gene therapies are expected to get the FDA green light. Given their precise targeting, gene therapies have largely been focused on oncology indications followed by rare genetic diseases.
Drug Discovery World
OCTOBER 16, 2023
From the Beatson Institute for Cancer Research in Glasgow, to Edinburgh Drug Discovery in the University of Edinburgh’s Institute for Genetics and Cancer (IGC). Revvity is a global company, and we continue to develop our Cambridge-based expertise in cell and gene therapy to support the global pharmaceutical industry.
pharmaphorum
JANUARY 10, 2022
On the back of the approvals for Pfizer/BioNTech and Moderna, suddenly there is a large amount of interest from big pharma companies to get involved in the mRNA space. This not only allowed Pfizer to establish a COVID-19 vaccine but the company also recently announced that it had begun a study testing an mRNA flu vaccine.
Expert insights. Personalized for you.
144 
Let's personalize your content